Milena Perez Mak

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Milena Perez Mak, Pan Tong, Lixia Diao et al. · Clinical Cancer Research · 2015 · 560 citations · Full text

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer et al. · The Lancet Oncology · 2023 · 175 citations · Full text

Fgfr Alterations, Medicine, Pathology +7

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 142 citations · Full text

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Siow Ming Lee, Christian Schulz, Kumar Prabhash et al. · The Lancet · 2023 · 142 citations

First-line Atezolizumab Monotherapy, Medicine, Pharmacology +8